Abstract: The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Abstract: The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Abstract: The present invention relates to modified amino acids of general formula 1

Abstract: The present invention relates to modified amino acids of general formula 1

Abstract: The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Abstract: The present invention relates to modified amino acids of general formula 1

Abstract: During the melting of glass from charging material in furnaces with burners and regenerators for the recovery of waste heat, oxygen and primary fuel are introduced into the area around the flame roots under slightly sub-stoichiometric conditions to cover the heat requirement of the melting process. In order to further reduce the levels of NOx, and CO in the waste gases by re-burning or post oxidation, secondary fuel and, further downstream, additional air are introduced beyond the flame in order to reduce the level of NOx, in or above the checkerwork by means of the secondary fuel and to carry out re-burning or post oxidation downstream by means of the supply of air, so that ultimately approximately stoichiometric combustion takes place. Before the waste gases enter a waste gas stack they are used to preheat the charging material in at least one raw material pre-heater.

Abstract: In a glass melting furnace, a radiation screen wall is installed between a melting area and a refining area with a refining bank. This radiation screen wall leaves a flow path above the melt surface of the glass bath for the return flow of at least part of the combustion gases from the refining area to the melting area. In order to suppress a return flow of already refined and very hot glass melt from the refining area into a melting area, but still allow the charging material to melt completely as early as possible, the furnace is operated to produce at least one upward current between the middle of the melting area and the front face of the refining bank in the glass melt.

Abstract: In the manufacturing of high melting point glasses with volatile components, in particular of glasses from the group of boron glasses and borosilicate glasses, a furnace is provided that has a superstructure, fossil fuel burners, and a melting tank. In front of a conditioning zone and a throat leading to an extraction zone, a step-shaped raised area in the bottom is provided which is formed continuously over the complete width of the melting tank. In order to suppress segregation or, respectively, phase separation, to protect the furnace construction materials and to enable problem-free operation, a temperature of at least 1600.degree. C.

Abstract: The present invention relates to carboxylic acid derivatives of the general formula ##STR1## in which R.sub.a to R.sub.c, A, B, D, E and X.sub.1 to X.sub.3 are as defined in claim 1, their tautomers, their stereoisomers including their mixtures, and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases, which have useful pharmacological properties, preferably aggregation-inhibiting inhibiting actions, medicaments containing these compounds, their use and processes for their preparation.

Abstract: The present invention relates to phenyl amidines of general formula (I), ##STR1## in which R.sup.1 to R.sup.5 are as defined in claim 1, their tautomers, their stereoisomers and their mixtures and their salts, especially their physiologically acceptable salts with inorganic or organic acids or bases also having valuable pharmacological properties, preferably aggregation-limiting effects, producing them.

Abstract: The invention relates to biphenyl derivatives of general formula ##STR1## wherein A to E and X are defined as in claim 1, the stereoisomers thereof, including their mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, preferably aggregation-inhibiting effects, pharmaceutical compositions containing these compounds and processes for preparing them.

Abstract: The present invention relates to piperazine derivatives of the general formula ##STR1## in which R.sub.a, Y.sub.1 to Y.sub.3 and E are defined herein, tautomers thereof, stereoisomers thereof, including their mixtures, and salts thereof, and in particular physiologically tolerated salts thereof with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, such as aggregation-inhibiting activity. This invention also relates to medicaments comprising these compounds and to processes for the preparation of these compounds.

Abstract: The invention relates to cyclic urea derivatives of general formula I ##STR1## wherein R.sub.a, R.sub.b, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.

Abstract: The invention relates to cyclic urea derivatives of general formula ##STR1## wherein R.sub.a, R.sub.b, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.

Abstract: The invention relates to cyclic derivatives of general formula ##STR1## wherein R.sub.a, R.sub.b, X and Y are as defined in claim 1, the tautomers, the stereoisomers including the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, pharmaceutical compositions containing the compounds and processes for preparing them.

Abstract: 5-Membered heterocyclic compounds, of which the following compounds are exemplary:(a) 4-??trans-4-(2-carboxyethyl)cyclohexyl!aminocarbonyl!-1-(4-piperidyl)imida zole,(b) 5-??trans-4-(2-carboxyethyl)cyclohexyl!aminocarbonyl!-4-methyl-2-(4-piperi dyl)-1,3-thiazole,(c) 5-??4-(carboxymethoxy)phenyl!aminocarbonyl!-4-methyl-2-(4-piperidyl)-1,3-t hiazole,(d) 5-??trans-4-(2-carboxyethyl)cyclohexyl!aminocarbonyl!-2-(4-piperidyl)-1,3, 4-thiadiazole,(e) 5-??4-(carboxymethoxy)phenyl!aminocarbonyl!-2-(4-piperidyl)-1,3,4-thiadiaz ole,(f) 5-??trans-4-(carboxymethoxy)cyclohexyl!aminocarbonyl!-2-(4-piperidyl)-1,3- thiazole,(g) 5-??4-(carboxymethoxy)phenyl!aminocarbonyl!-2-(4-piperidyl)-1,3-thiazole,(h) 5-??trans-4-(2-carboxyethyl)cyclohexyl!aminocarbonyl!-2-(4-piperidyl)-1,3- thiazole, and(i) 4-??trans-4-carboxycyclohexyl!aminocarbonyl!-1-?2-(4-piperidyl)ethyl!imida zole.

Abstract: A method of operating a regenerative glass melting furnace with end-firing or cross-firing utilizes burners to provide sub-stoichiometric combustion and super-stoichiometric combustion along the sidewalls or transverse walls of the furnace and equipment associated with the method. Fuel supply is controlled so that overall combustion is stoichiometric.

Abstract: The invention relates to biphenyl derivatives of general formula ##STR1## wherein A to E and X are defined as in claim 1, the stereoisomers thereof, including their mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, preferably aggregation-inhibiting effects, pharmaceutical compositions containing these compounds and processes for preparing them.

Abstract: A tank furnace for the inertization of non-flammable batch, which contains hazardous substances, metals and less than 10% by weight of carbon, by vitrification with glass forming aggregates by producing a glassy melt. The furnace has a batch charging device and a tank, on the rim of which a furnace crown rests, electrodes for heating the melt, a supply of oxidizing gases to the melt and, as an outlet for the melt, an overflow channel which can be heated. Nozzles are installed in the bottom of the tank to introduce oxidizing gases in order to reduce the eluate values, and the electrodes are immersed in the melt from above. It is preferable to install the nozzles at sloping sidewalls of the tank which slope upwardly and outwardly.